Study #2018-0089
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apaluta
MD Anderson Study Status
Not Accepting
Treatment Agent
GnRH, Bicalutamide, Abiraterone, Prednisone, Apalutamide
Description
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Phase II
Physician name:
Karen Hoffman
Department:
Radiation Oncology
For general questions about clinical trials:
1-855-798-1207
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.